コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 greater risk of constipation, insomnia, and Restless Legs.
2 hat has been implicated as a risk factor for restless legs display important features of the syndrome
3 reathlessness, feeling faint, dizziness, and restless legs, especially among men [for all listed symp
5 gand binding and RLS severity (international restless legs scale, IRLS) in areas serving the medial p
6 ility, depression, difficulty concentrating, restless legs syndrome (32%-40%), pica (40%-50%), dyspne
7 depression (g = 1.10, 95% CI [1.06, 1.15]), restless legs syndrome (g = 1.41, 95% CI [1.25, 1.56]),
8 e were performed on patients with idiopathic restless legs syndrome (iRLS) who were not currently on
9 ted odds ratio =1.26; 95% CI = 1.02-1.54) or restless legs syndrome (n = 108, adjusted odds ratio = 1
10 med as the strongest genetic risk factor for restless legs syndrome (odds ratio 1.92, 95% CI 1.85-1.9
11 (odds ratio [OR], 4.49; 95% CI, 3.98-5.06), restless legs syndrome (OR, 3.73; 95% CI, 3.39-4.09), bi
12 In addition, there were associations with restless legs syndrome (OR, 4.19; 95% CI, 3.91-4.50), sl
14 ies suggested a positive association between restless legs syndrome (RLS) and coronary heart disease
15 Most research on the association between restless legs syndrome (RLS) and depression has involved
17 n the urge to move and sensory discomfort of restless legs syndrome (RLS) and properties of melanocor
18 minergic medications relieve symptoms of the restless legs syndrome (RLS) but have the potential to c
28 revious cross-sectional study, we found that restless legs syndrome (RLS) was associated with erectil
29 isual perceptive computing (19 patients with restless legs syndrome (RLS), 21 patients with obstructi
32 spinal cord is implicated in the etiology of Restless Legs Syndrome (RLS), which is more prevalent in
33 1 dopaminergic systems in the development of restless legs syndrome (RLS)-like movements during sleep
37 ales (p = 0.007), had a higher proportion of restless legs syndrome (RLS; p < 0.001), had a higher bo
38 or to natural menopause had a higher risk of restless legs syndrome after the index date compared wit
39 oophorectomy, there was an increased risk of restless legs syndrome among women without a benign ovar
40 ls were isolated from the motor cortex of 11 restless legs syndrome and 14 control brains obtained at
41 entified and replicated 13 new risk loci for restless legs syndrome and confirmed the previously iden
42 small effects have been identified for both restless legs syndrome and narcolepsy with cataplexy.
45 r, a significant percentage of patients with restless legs syndrome are responsive to intravenous iro
47 [21.0%] vs 135 women [8.2%]; P < .001), and restless legs syndrome before the index date (32 women [
48 loss of iron regulatory protein activity in restless legs syndrome brain tissue further implicates t
51 f relative brain iron deficiency reported in restless legs syndrome brains may underlie the problems
53 ns in the iron management protein profile in restless legs syndrome compared with controls at the sit
54 on in the brain is lower in individuals with restless legs syndrome compared with neurologically norm
55 ng of the molecular mechanisms that underlie restless legs syndrome could lead to new treatment optio
62 EAP4, VAV3) resided in the vicinity of known restless legs syndrome loci, whereas 5 (BBS7, CADM1, CRE
65 in and its receptor in the microvessels from restless legs syndrome was significantly decreased compa
66 controls and 14 individuals who had primary restless legs syndrome was subjected to histochemical st
67 mptoms of iron deficiency (fatigue, pica, or restless legs syndrome) and should be considered for tho
69 found between frequent insomnia symptoms and restless legs syndrome, aging, and cardiometabolic, beha
71 on's disease, dystonia, Tourette's syndrome, restless legs syndrome, and akathisia, have traditionall
72 nized conditions (motor stereotypy disorder, restless legs syndrome, and infantile masturbation) as w
73 rcadian disorders, obstructive sleep apnoea, restless legs syndrome, and rapid eye movement (REM) sle
74 onia, chorea, tics, myoclonus, stereotypies, restless legs syndrome, and various other disorders with
76 id eye movement sleep behavior disorder, and restless legs syndrome, as well as circadian disorders,
77 This issue provides a clinical overview of restless legs syndrome, focusing on diagnosis, treatment
78 medical condition, obstructive sleep apnea, restless legs syndrome, idiopathic insomnia, and circadi
80 navian cohorts and on other sleep disorders (restless legs syndrome, insomnia) and sleep traits (dura
81 xt of another primary sleep disorder such as restless legs syndrome, or secondary to another underlyi
82 value of sex, daytime somnolence, insomnia, restless legs syndrome, sleep apnoea, urinary dysfunctio
83 f sleep are imperfect and may be affected by restless legs syndrome, these findings provide new biolo
84 including central sleep apnea, insomnia, and restless legs syndrome-in AF pathogenesis and progressio
96 the activity of this protein is decreased in restless legs syndrome; a finding similar to our earlier